原发性乳腺b细胞非霍奇金淋巴瘤。病例报告及文献回顾

Q3 Medicine
Leopoldo Santiago-Sanabria, Julieta Garza-Arrieta, Gina Daniela Porras-Ibarra, Montserrat Malfavón-Farias
{"title":"原发性乳腺b细胞非霍奇金淋巴瘤。病例报告及文献回顾","authors":"Leopoldo Santiago-Sanabria,&nbsp;Julieta Garza-Arrieta,&nbsp;Gina Daniela Porras-Ibarra,&nbsp;Montserrat Malfavón-Farias","doi":"10.18597/rcog.3844","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To report a case of primary breast B-cell non-Hodgkin’s lymphoma (PBL) and to conduct a literature review of its diagnosis and treatment.</p><p><strong>Materials and methods: </strong>Case report of an 80-year-old female patient who presented to a private referral institution in Mexico, with PBL. She was also diagnosed with primary liver melanoma by means of targeted biopsy and pathology testing. The patient received treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), quadrantectomy, lymph node dissection and radiotherapy. The PBL showed good response but, because of progression of the second primary tumor, the patient went on to receive palliative care. A review of the literature was conducted in Medline via PubMed, LILACS and Google Scholar. Cohort studies, case reports and case series in patients with PBL that discussed diagnosis, treatment and prognosis of this disease, published in English and Spanish between 2000 and 2022, were included.</p><p><strong>Results: </strong>Overall, 23 titles were identified, of which 17 consisting of case reports and case series met the inclusion criteria. The majority of patients received R-CHOP as chemotherapy regimen, with irradiation as adjunct therapy. Close to 80 % went into complete remission. The most frequent site of recurrence was the central nervous system. Five-year survival was 83.6 % in the included studies.</p><p><strong>Conclusions: </strong>At present, the CHOP regimen, with or without rituximab and usually accompanied by radiotherapy, is the most widely used and the only one that has shown a positive impact on survival. Additional randomized clinical trials are needed in order to gain a clearer insight into the effectiveness and safety of these treatments.</p>","PeriodicalId":35675,"journal":{"name":"Revista Colombiana de Obstetricia y Ginecologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/09/2463-0225-rcog-74-01-3844.PMC10174716.pdf","citationCount":"0","resultStr":"{\"title\":\"Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature\",\"authors\":\"Leopoldo Santiago-Sanabria,&nbsp;Julieta Garza-Arrieta,&nbsp;Gina Daniela Porras-Ibarra,&nbsp;Montserrat Malfavón-Farias\",\"doi\":\"10.18597/rcog.3844\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To report a case of primary breast B-cell non-Hodgkin’s lymphoma (PBL) and to conduct a literature review of its diagnosis and treatment.</p><p><strong>Materials and methods: </strong>Case report of an 80-year-old female patient who presented to a private referral institution in Mexico, with PBL. She was also diagnosed with primary liver melanoma by means of targeted biopsy and pathology testing. The patient received treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), quadrantectomy, lymph node dissection and radiotherapy. The PBL showed good response but, because of progression of the second primary tumor, the patient went on to receive palliative care. A review of the literature was conducted in Medline via PubMed, LILACS and Google Scholar. Cohort studies, case reports and case series in patients with PBL that discussed diagnosis, treatment and prognosis of this disease, published in English and Spanish between 2000 and 2022, were included.</p><p><strong>Results: </strong>Overall, 23 titles were identified, of which 17 consisting of case reports and case series met the inclusion criteria. The majority of patients received R-CHOP as chemotherapy regimen, with irradiation as adjunct therapy. Close to 80 % went into complete remission. The most frequent site of recurrence was the central nervous system. Five-year survival was 83.6 % in the included studies.</p><p><strong>Conclusions: </strong>At present, the CHOP regimen, with or without rituximab and usually accompanied by radiotherapy, is the most widely used and the only one that has shown a positive impact on survival. Additional randomized clinical trials are needed in order to gain a clearer insight into the effectiveness and safety of these treatments.</p>\",\"PeriodicalId\":35675,\"journal\":{\"name\":\"Revista Colombiana de Obstetricia y Ginecologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/09/2463-0225-rcog-74-01-3844.PMC10174716.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Colombiana de Obstetricia y Ginecologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18597/rcog.3844\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Obstetricia y Ginecologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18597/rcog.3844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:报告1例原发性乳腺b细胞非霍奇金淋巴瘤(PBL),并对其诊断和治疗进行文献回顾。材料与方法:病例报告一位80岁女性患者在墨西哥一家私人转诊机构就诊,患有PBL。通过靶向活检和病理检查,她也被诊断为原发性肝黑色素瘤。患者接受R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱、强的松)、四象限切除术、淋巴结清扫和放疗。PBL显示出良好的反应,但由于第二原发肿瘤的进展,患者继续接受姑息治疗。通过PubMed, LILACS和Google Scholar在Medline上对文献进行了综述。纳入了2000年至2022年间以英语和西班牙语发表的PBL患者的队列研究、病例报告和病例系列,这些研究讨论了该病的诊断、治疗和预后。结果:共鉴定出23篇标题,其中17篇由病例报告和病例系列组成,符合纳入标准。大多数患者采用R-CHOP作为化疗方案,放疗作为辅助治疗。接近80%的患者完全缓解。最常见的复发部位是中枢神经系统。在纳入的研究中,5年生存率为83.6%。结论:CHOP方案目前应用最广泛,且唯一显示出对生存有积极影响的方案,无论是否使用利妥昔单抗,通常伴有放疗。为了更清楚地了解这些治疗的有效性和安全性,还需要进行更多的随机临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature

Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature

Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature

Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature

Objectives: To report a case of primary breast B-cell non-Hodgkin’s lymphoma (PBL) and to conduct a literature review of its diagnosis and treatment.

Materials and methods: Case report of an 80-year-old female patient who presented to a private referral institution in Mexico, with PBL. She was also diagnosed with primary liver melanoma by means of targeted biopsy and pathology testing. The patient received treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), quadrantectomy, lymph node dissection and radiotherapy. The PBL showed good response but, because of progression of the second primary tumor, the patient went on to receive palliative care. A review of the literature was conducted in Medline via PubMed, LILACS and Google Scholar. Cohort studies, case reports and case series in patients with PBL that discussed diagnosis, treatment and prognosis of this disease, published in English and Spanish between 2000 and 2022, were included.

Results: Overall, 23 titles were identified, of which 17 consisting of case reports and case series met the inclusion criteria. The majority of patients received R-CHOP as chemotherapy regimen, with irradiation as adjunct therapy. Close to 80 % went into complete remission. The most frequent site of recurrence was the central nervous system. Five-year survival was 83.6 % in the included studies.

Conclusions: At present, the CHOP regimen, with or without rituximab and usually accompanied by radiotherapy, is the most widely used and the only one that has shown a positive impact on survival. Additional randomized clinical trials are needed in order to gain a clearer insight into the effectiveness and safety of these treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Colombiana de Obstetricia y Ginecologia
Revista Colombiana de Obstetricia y Ginecologia Medicine-Obstetrics and Gynecology
CiteScore
1.00
自引率
0.00%
发文量
21
审稿时长
20 weeks
期刊介绍: The Revista Colombiana de Obstetricia y Ginecología was founded in January 1949. It is the Federación Colombiana de Asociaciones de Obstetricia y Ginecología"s official periodic publication (formerly known as the Sociedad Colombiana de Obstetricia y Ginecología). It is published quarterly and the following abbreviation should be used when citing the journal: Rev. Colomb. Obstet. Ginecol. The publication is authorized by Mingobierno resolution 218/1950.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信